NCT01493518View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

June 30, 2013

Conditions
Psoriasis
Interventions
DRUG

AMG 557 or PLACEBO

Multiple subcutaneous doses of AMG 557 or Placebo on Days 1, 8, 15, 29, 43, 57 and 71.

Trial Locations (6)

35233

Research Site, Birmingham

75231

Research Site, Dallas

84107

Research Site, Salt Lake City

89511

Research Site, Reno

97239

Research Site, Portland

Unknown

Dallas

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY